Machnicki Marcin M, Stoklosa Tomasz
Department of Immunology, Medical University of Warsaw, Banacha 1A, 02-097 Warsaw, Poland.
Department of Immunology, Medical University of Warsaw, Banacha 1A, 02-097 Warsaw, Poland.
Blood Cells Mol Dis. 2014 Jun-Aug;53(1-2):77-83. doi: 10.1016/j.bcmd.2014.01.001. Epub 2014 Feb 2.
BRAF oncogenic kinase has become a target for specific therapy in oncology. Genetic characterization of a predominant V600E mutation in melanoma, thyroid cancer, and other tumors became a focus for developing specific inhibitors, such as vemurafenib or dabrafenib. Our knowledge regarding the role of mutated BRAF in hematological malignancies has grown quickly as a result of new genetic techniques such as next-generation sequencing. This review summarizes current knowledge regarding the role of BRAF in lymphoid and myeloid neoplasms, with a focus on hairy-cell leukemia, Langerhans cell histiocytosis, and Erdheim-Chester disease.
BRAF致癌激酶已成为肿瘤学中特异性治疗的靶点。黑色素瘤、甲状腺癌及其他肿瘤中主要的V600E突变的基因特征成为开发特异性抑制剂（如维莫非尼或达拉非尼）的重点。由于新一代测序等新基因技术，我们对突变型BRAF在血液系统恶性肿瘤中的作用的认识迅速增加。本综述总结了目前关于BRAF在淋巴和髓系肿瘤中的作用的知识，重点关注毛细胞白血病、朗格汉斯细胞组织细胞增多症和 Erdheim-Chester病。
